Refleksi : Bagaimana penyakit ini di NKRI? Tidak ada? Bila ada berapa banyak?

http://weekly.ahram.org.eg/2010/983/fe1.htm

28 January - 3 February 2010
Issue No. 983
Published in Cairo by AL-AHRAM established in 1875

Hope against hepatitis C
A new centre for treating hepatitis C is offering new hope to patients, but 
ways of combating the threat effectively have still to be found, writes Ahmed 
Abu Ghazala 

--------------------------------------------------------------------------------
     
      Old habits of shaving are one of the causes of HCV infection for the less 
affluent
      photo: Ahmed Shehata 
--------------------------------------------------------------------------
     
Finding a person infected by the hepatitis C virus (HCV) is not difficult. 
Simply ask a friend, or a colleague, or even the doorman, and they will 
eventually tell you they have either heard about someone who is infected by the 
disease, or that they know of someone, whether a relative or a friend. 

According to Minister of Health Hatem El-Gabali, demographic studies have shown 
that some 9.8 per cent of the Egyptian population is infected with the 
hepatitis C virus, and the number of infected citizens may have reached nine 
million.

Mohamed Hamdi, a successful journalist in his 40s, is one of the millions 
infected by the disease. Hamdi remembers how in 1995 he had an endoscopy. 
"While it was supposed to be a simple surgery, I came out with other 
complications," he said. After surgery, he suffered from abdominal pain, 
diarrhea and other symptoms. Concerned by these, he hurried to the doctor and 
had tests, which turned out to be negative for any specific disease. 

However, many years later in 2007, Hamdi was diagnosed with high blood 
pressure, and he had tests which showed unusually high liver enzymes. After 
further checkups, to his dismay Hamdi discovered that he was infected with HCV.

"Almost a quarter of the Egyptian population is infected by different hepatic 
diseases, including schistosomiasis, cirrhosis, hepatitis A, B or C, or liver 
cancer. We should be treating hepatic diseases as a national threat," said 
Hassan El-Shenawi, professor of hepatology at the National Liver Institute at 
Menofiya University, at a recent training session on HCV at the Al-Qasr Al-Aini 
Medical School of Cairo University.

The numbers of Egyptians infected by HCV and other hepatic diseases now exceeds 
the populations of many other countries in the world. Moreover, many infected 
people do not know that they have been infected. 

However, hope may now be on its way. In order to deal with the threat of such 
diseases, the Al-Qasr Al-Aini Medical School has established a new centre for 
treating hepatic patients. 

"It is anticipated that the number of HCV patients will increase during the 
2012 to 2020 period, and that's why it was important to think practically of 
how to face the spread of the disease," said Gamal Esmat, professor of 
hepatology and tropical medicine at the Al-Qasr Al-Aini Medical School, 
president of the International Association for the Study of the Liver (IASL), 
and director of the new centre.

The first goal of the new centre, the Al-Qasr Al-Aini Centre for Hepatic 
Diseases, is to open its doors to all patients who need its services. "The 
centre can treat 180 patients daily. We have 25 doctors, apart from those 
conducting laboratory tests," Esmat said, adding that the centre has agreed 
special prices with drug companies to ensure that drugs are available at 
reduced prices. 

The centre provides patients and their families with vaccinations and 
prophylactic procedures. It does not only serve patients, and aims instead to 
become a training centre for doctors in dealing with different kinds of hepatic 
disease, becoming a centre for research into the development of new treatments 
for hepatitis B and C.

Statements made at the opening of the new centre were optimistic about its 
potential. "We lack informed scientific research to back up our work, so the 
opening of this centre makes me feel more confident," said Abdel-Hamid Abaza, 
head of the political bureau at the Ministry of Health. 

"We are offering all kinds of help as a public institution responsible for 
public health in Egypt, and we will support all the efforts of the Al-Qasr 
Al-Aini Medical School," Abaza said.

Dean of the Al-Qasr Al-Aini Medical School Ahmed Farid said that the school is 
working in collaboration with other Egyptian and international centres and that 
the establishment of the centre, the first in Egypt specialising in hepatology, 
was part of the school's larger public-health efforts.

According to Hani Hilal, minister of higher education and scientific research, 
it is also time for the private sector and NGOs to participate in financing 
similar projects, in order to help find solutions to such endemic diseases.

Hossam Kamel, president of Cairo University, said HCV had been at the top of 
the university's research agenda for the 2006 to 2011 period, and that the 
centre would bolster efforts to combat the disease.

Yet, despite these hopeful developments, HCV presents other predicaments. 
According to Esmat, some 70 per cent of HCV infections come from medical 
sources through the use of infected instruments during various hospital 
procedures. 

"It is a huge problem that when a patient enters a hospital to treat a certain 
disease, he or she then comes out with a more dangerous one," Esmat said.

The other 30 per cent of infections are thought to come from instruments used 
by multiple users, such as shaving razors or toothbrushes. 

"The problem is that infection is taking place randomly," Hamdi said in an 
interview with Al-Ahram Weekly. "HCV is spread among poorer people in Egypt, 
who use each other's personal items and are treated in public hospitals. Such 
people often do not know that they have been infected. They don't have medical 
insurance and can't afford treatment."

Esmat said that the only way to prevent risks of HCV infection was to use 
medical instruments once and then dispose of them. Normal high-temperature 
cleaning procedures were not sufficient to eradicate all risk of passing on the 
disease. However, using instruments only once was too expensive for the public 
hospitals, and "that is why the public hospitals aren't safe enough. If they 
used instruments only once, they would have to reduce the services they offer," 
he said. 

A way should be found of providing instruments to public hospitals at cheaper 
prices, he said. 

In order to avoid infection by HCV, people should avoid tattoos or using the 
same needles, and if possible they should only use their own medical 
instruments. "The problem occurs when a young person uses a friend's equipment, 
thinking that he looks healthy enough and without realising that HCV doesn't 
have clear symptoms and anyone can be infected without knowing it."

While knowledge of one's serological status, especially in the early stages of 
the disease, can massively improve prognosis, many people only find out about 
their infection after many years of leading normal lives.

Hamdi, for example, explains that, "I had many checkups prior to the last one, 
but no one told me I was infected with HCV, although I must have been infected 
since the original surgery."

Treatment for HCV consists of interferon and ribavirin therapy, interferon as 
an injection taken once a week and ribavirin as tablets taken three times a 
day. The therapy is very expensive and has many side effects, but it is the 
only one at present that is internationally recognised.

Side effects of treatment for HCV vary from one patient to the next, being 
sometimes mild but sometimes more severe, and including depression, coughing, 
loss of weight, dizziness, aching joints, abdominal and back pain, nausea, 
vomiting, diarrhea, skin problems, mild hair loss, reduced white and red blood 
cell count, anorexia, congestion and elevated liver enzymes.

The price of one shot of interferon is LE1,390, with the therapy as a whole 
costing some LE6,000 a month. Fortunately for many patients, the Ministry of 
Health is able to provide interferon shots at LE480, but this is still not 
cheap for the average citizen.

"It's a huge problem. If you can't afford therapy, and you don't have medical 
insurance, you will remain infected and without treatment until you die," Hamdi 
said.

Successful treatment takes place in between 50 and 60 per cent of cases. For 
Hamdi, the treatment consisted of his taking interferon shots weekly and 
ribavirin tablets for one year, but he decided to stop treatment after six 
months, feeling that it was not effective. 

"Successful treatment takes place in only 40 per cent of cases," Hamdi 
explained. "I may try something else if a new treatment comes along. Research 
has shown that new treatments may become available that will raise success 
rates to 80 per cent," he said.

In cases where a patient is not undergoing therapy, treatment consists of 
taking anti- oxidants, vitamins, and liver-enhancing supplements, which cost 
LE300-500 a month.

An Egyptian-manufactured interferon shot is also on the market, manufactured in 
collaboration with a German company, and this is available from the Ministry of 
Health at LE220. According to Esmat, "the Egyptian medication achieves similar 
results to the American-Swiss one, which is the internationally recognised 
treatment. Many Egyptians prefer to use the Egyptian product because it is much 
cheaper."

Esmat told the Weekly that the Egyptian product was undergoing improvements in 
order to increase its effectiveness and decrease side effects. The reason the 
Egyptian medication was not internationally recognised was because the 
American-Swiss product held the international patent rights. "When this patent 
ends, our medication will also be recognised," he said.

As a person living with HCV and also a journalist, Hamdi is in a good position 
to promote awareness about the disease. Sometimes he writes out of anger at 
people selling false hope to patients with HCV by promoting herbal medications 
or other non-recognised forms of treatment. 

"These treatments are not based on scientific research. One person tries 
something on two or three patients and then claims to have discovered a new 
therapy. I try to raise people's awareness of this problem."

El-Shenawi is also concerned at the promotion of herbal treatments for HCV on 
satellite television channels. "These so-called treatments are a swindle," he 
says. "There are no therapies for HCV apart from those based on scientific 
research. If people listen to the fraudulent claims made for herbal treatments, 
this could lead to further complications later."

For his part, Esmat prefers to leave the matter to people to decide. "If I had 
really found a perfect therapy for HCV, as they claim on TV, I would be awarded 
the Nobel Prize in medicine and journalists would be running after me. I 
wouldn't have to pay a TV station to promote my therapy," he said.

However, he also laments the fact that the disease is not treated as a serious 
problem in the media. "The most important topic in Egypt as far as the media is 
concerned is swine flu, which barely killed more than 100 people, while many 
more people are dying every year from complications from HCV. Much more is 
spent every year on interferon therapy and liver surgery than is ever spent on 
swine flu." 

It is this lack of public awareness that is the main reason behind the spread 
of HCV in Egypt. The peak of the virus's spread was in the 1960s and 1970s, 
when needles used to treat schistosomiasis patients were used for several 
patients at a time. 

For Esmat, television would be the best way of raising public awareness, though 
Hamdi cautions that the authorities also have a role to play.

"A main problem is the lack of information. If the Ministry of Health sent 
awareness convoys to all Egypt's governorates, it could conduct tests that 
would also provide us with information about the extent of the disease in the 
country and effectively raise people's awareness."

Before the opening of the new Al-Qasr Al-Aini centre, a training session was 
conducted for journalists about HCV. Those present were asked questions about 
the disease, and almost 20 per cent of the answers were incorrect. 

Many Egyptians do not know anything about the disease. "What is HCV? No, I 
don't know anything about it," said Ali Ragheb, 46, a janitor at a building in 
Nasr City. When Ragheb was told that HCV was a disease that could infect the 
liver, he commented that "many people suffer from liver infections. In my 
hometown of Minya I know a woman who is suffering from something similar and is 
being treated at the expense of the state."

Although Ragheb doesn't know anything about HCV, he said that he asks the 
barber to change his razor before shaving his beard, and he is aware that he 
must use clean needles if injected. "I know that these are important 
requirements and that many diseases come from infected blood," he said.

For Nehmedo Orabi, 39, a maid, the difference between hepatitis A, B, or C is 
slim, since for her they are only letters of the alphabet. "HCV is a disease 
that infects the liver. I think it infects those who eat unhygienic food or 
drinks," she said. Although the disease Orabi is referring to is hepatitis A, 
she also said that her brother had been infected by HCV, though this turned out 
to be hepatitis A, not hepatitis C.

Like many poorer people in Egypt, Orabi's attitude was that "everything is in 
God's hands."

For Hamdi El-Sayed, head of the Doctors' Syndicate and head of the medical 
committee of the People's Assembly, the media is not making sufficient efforts 
to combat the disease, though the Ministry of Health is running campaigns in 
schools and universities to raise students' awareness of HCV and inoculate them 
against hepatitis B.

El-Sayed added that the government had spent LE250 million in 2009 to help 
treat HCV patients, and that 15 further centres had been established in various 
governorates to treat HCV, along with the formation of a national association 
to collect donations to fund liver surgery and other forms of treatment.

The government was trying to decrease infections in public hospitals, though 
this should be accompanied by greater awareness of hygiene among the public as 
a whole.

"The public should be aware of such issues when going to the barber, or the 
dentist," El-Sayed said. "The government cannot inspect everyone. However, if 
people are aware of the disease, they will force practitioners to sterilise 
their tools."

Yet, even though Egypt has made many achievements in fighting HCV and hepatic 
diseases in general, the danger these diseases present is escalating.

According to El-Shenawi, "we can only deal with HCV through a powerful 
nationwide campaign. If things get worse, we will face a very serious 
situation." 

Infection by HCV 

HCV can be transmitted in four main ways:

- By blood transfusion or blood products, or by organ transplant from an 
infected person;

- By instruments carrying the blood of an infected person, including 
instruments used for piercings and tattoos, dental instruments, shaving 
instruments, toothbrushes, needles, or other instruments that may cause wounds 
or blood-to-blood contact;

- By infection from the mother to her child, though this is true of only three 
to five per cent of total infections;

- By sexual relations, though these are rarely the cause of infection with HCV.

Did you know? 

HEPATITIS C is an infectious disease that was discovered in 1989 and is 
transmitted through infected blood. It affects patients' livers, and without 
adequate treatment can develop to cause cirrhosis, or liver cancer. If this 
happens, a patient is required to have a liver transplant, though the virus may 
recur even after transplantation. 

HCV has six genotypes and 52 subtypes. The fourth genotype is the one infecting 
90- 95 per cent of Egyptian patients. Unlike for hepatitis B, there is no 
vaccine against hepatitis C. Early discovery of HCV infection considerably 
improves prognosis, with successful treatment being possible in up to 98 per 
cent of cases. This rate falls the later the infection is discovered. 


[Non-text portions of this message have been removed]

Kirim email ke